MedTrace Logo

A Phase I Study of Famitinib Malate in Patients With Solid Tumor

NCT01762280 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2018-04-18

No results posted yet for this study

Summary

Famitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Famitinib in patients with solid tumor

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

Famitinib Malate Capsule

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jinwan Wang, M.D · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Dafang Zhong, Ph.D · Chinese Academy of Science Shanghai Institution of Materia Medica

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-04-30
Completion
2012-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01762280 on ClinicalTrials.gov